Published 3 months ago

EU regulators under fire after rejecting breakthrough Alzheimer’s medicine

Summary by Ground News

The European Union’s drug regulator has come under fire for blocking a breakthrough Alzheimer’s drug that already has market approval in five other countries. European Medicines Agency (EMA) committee recommended on Friday that Leqembi, also known as lecanemab, be denied market authorisation in the EU despite the treatment reducing cognitive decline in Alzheimer’s patients by 27 per cent in a late-stage clinical trial.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year